DEERFIELD, Ill.–(BUSINESS WIRE)–Baxter International, Inc. (NYSE: BAX), a global leader in sterile medication production and delivery, today announced the FDA approval of Bivalirudin in 0.9 percent Sodium Chloride Injection (bivalirudin). Bivalirudin is a specific and direct thrombin inhibitor indicated for use as an anticoagulant in patients undergoing percutaneous coronary intervention (PCI), a common […]